These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22816154)

  • 1. My doctor wanted me to start taking Evista (raloxifene hydrochloride) for osteoporosis, but I'm worried because the drug is linked to a risk of blood clots. I have mild hypertension that I manage with medications, diet and exercise. Do you think the drug is safe?
    Heart Advis; 2010 May; 13(5):8. PubMed ID: 22816154
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteoporosis treatment: raloxifene (Evista) and stroke mortality.
    Wooltorton E
    CMAJ; 2006 Jul; 175(2):147. PubMed ID: 16804122
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ].
    Ono K; Ohashi S; Tanaka S
    Clin Calcium; 2014 Mar; 24(3):401-6. PubMed ID: 24576937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke in relation to use of raloxifene and other drugs against osteoporosis.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Osteoporos Int; 2011 Apr; 22(4):1037-45. PubMed ID: 20449570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. By the way, doctor. I'm 60 and have osteoporosis. My doctor is recommending Fosamax, but I'm concerned about jawbone problems. Are there any other drugs I can take?
    Robb-Nicholson C
    Harv Womens Health Watch; 2006 Dec; 14(4):8. PubMed ID: 17299880
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combination therapy for osteoporosis].
    Hagino H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():316-20. PubMed ID: 18161124
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current and future prospects for anti-osteoporotic drugs].
    Inoue D
    Nihon Yakurigaku Zasshi; 2007 Sep; 130(3):206-9. PubMed ID: 17878616
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of currently marketed anti-osteoporosis medications.
    Reginster JY; Neuprez A; Dardenne N; Beaudart C; Emonts P; Bruyere O
    Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):809-34. PubMed ID: 25432354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mandibular Osteonecrosis Associated With Raloxifene.
    Pontes HAR; Souza LL; Uchôa DCC; Cerqueira JMM
    J Craniofac Surg; 2018 May; 29(3):e257-e259. PubMed ID: 29303860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of comparative effectiveness of treatments to prevent fractures.
    Stock JL; Mershon JL; Schoenfeld MJ
    Ann Intern Med; 2008 Jun; 148(11):885; author reply 887. PubMed ID: 18519941
    [No Abstract]   [Full Text] [Related]  

  • 11. Duration of treatment for osteoporosis.
    Idolazzi L; Fassio A; Gatti D; Tamanini S; Viapiana O; Rossini M; Adami S
    Reumatismo; 2013 Mar; 65(1):22-35. PubMed ID: 23550257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and prevention of osteoporosis in patients with decreased renal function].
    Vestergaard P; Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):227-30. PubMed ID: 18282452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of SERMs on bone health. The potential of SERM in the care of chronic kidney disease-mineral bone and disorders].
    Hamano T
    Clin Calcium; 2010 Mar; 20(3):373-9. PubMed ID: 20190367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Raloxifene in postmenopausal women].
    Trémollières F; Ribot C
    Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].
    Iwamoto J
    Clin Calcium; 2010 Mar; 20(3):396-407. PubMed ID: 20190370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs.
    Fuggle NR; Cooper C; Harvey NC; Al-Daghri N; Brandi ML; Bruyere O; Cano A; Dennison EM; Diez-Perez A; Kaufman JM; Palacios S; Prieto-Alhambra D; Rozenberg S; Thomas T; Tremollieres F; Rizzoli R; Kanis JA; Reginster JY
    Drugs; 2020 Oct; 80(15):1537-1552. PubMed ID: 32725307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.
    Hamaya E; Sowa H
    Menopause; 2014 Jan; 21(1):109-10. PubMed ID: 24281238
    [No Abstract]   [Full Text] [Related]  

  • 19. [CORE study].
    Mizunuma H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():294-8. PubMed ID: 18161121
    [No Abstract]   [Full Text] [Related]  

  • 20. [Combination therapy for osteoporosis].
    Kishimoto H
    Nihon Rinsho; 2009 May; 67(5):975-9. PubMed ID: 19432119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.